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Introduction: The BIM deletion polymorphism in intron 2 was found 
in a significant percent of the Asian population. Patients with epider-
mal growth factor receptor (EGFR) mutant lung cancers harboring 
this BIM polymorphism have shorter progression free survival and 
overall response rates to EGFR tyrosine kinase inhibitors. However, 
the association between the BIM deletion polymorphism and lung 
cancer risk is unknown.
Methods: The BIM deletion polymorphism was screened by poly-
merase chain reaction in 765 lung cancer cases and 942 healthy 
individuals.
Results: Carriers possessing one allele of the BIM polymorphism 
were observed in 13.0% of control cases and 12.8% of lung cancer 
cases, similar to incidence rates reported earlier in healthy individuals. 
Homozygote for the BIM polymorphism was observed in four of 942 
healthy controls and three of 765 lung cancer cases. The frequency of 
the BIM deletion polymorphism in lung cancer patients was not related 
to age, sex, smoking history, or family history of lung cancer. The BIM 
deletion polymorphism was found in 30 of 212 patients with EGFR 
wild type lung cancers and 16 of 120 patients with EGFR mutant lung 
cancers. The frequency of the BIM polymorphism is similar between 
cancers with wild type EGFR and mutated EGFR (p = 0.78).
Conclusion: The BIM deletion polymorphism was not associated 
with lung cancer susceptibility. Furthermore, the BIM polymorphism 
is not associated with EGFR mutant lung cancer.
Key Words: BIM polymorphism, Lung cancer, Susceptibility, EGFR 
mutation.
(J Thorac Oncol. 2015;10: 59–66)
Lung cancer is a leading cause of cancer death in developed countries. Loss of apoptosis is critical for both tumori-
genesis and resistance to drug therapies. The BCL-2 family 
member proteins play important roles in regulating apopto-
sis in response to a wide variety of cellular signals, includ-
ing DNA damage and growth factor withdrawal.1,2 The BCL-2 
family consists of three subfamilies1,2: pro-survival members 
(e.g., BCL-2 and MCL1), pro-apoptotic members (i.e., BCL-2 
homology domain 3 [BH3]-only proteins including BIM and 
PUMA, and the pro-apoptotic BAX and BCL-2 antagonist/
killer [BAK]). BIM is a member of the BH3-only proteins that 
binds and neutralizes the anti-apoptotic BCL2 family mem-
bers, as well as directly activating BAX and BAK to induce 
apoptosis. In a number of different cancer types, both in vitro 
and in vivo studies have evidenced that BIM is essential for 
apoptosis following targeted therapy administration.2–10
Activating mutations in the epidermal growth factor 
receptor (EGFR) renders EGFR the primary driver oncogene 
in lung cancer. EGFR tyrosine kinase inhibitors (EGFR-TKIs) 
have provided significant survival benefit in patients harbor-
ing EGFR mutations. However, these studies have indicated 
that 20 to 40% of patients are primarily resistant to EGFR-
TKIs.11–13 In oncogene addicted cancers like EGFR mutant 
lung cancers, survival signals derived from the oncogene 
regulate the expression and the interaction of BCL-2 family 
members. In particular, BIM is a key mediator of apoptosis in 
response to EGFR-TKIs.3–5,10,14–16 EGFR-TKIs downregulate 
MAPK signaling that leads to upregulation of BIM expres-
sion in these cancers. Importantly, several studies have shown 
that low levels of pretreatment, functional BIM in tumor cell 
lines and patients’ tumors is related to a mitigated apoptotic 
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response and lack of efficacy following EGFR-TKI treat-
ment.4,5,10,15–21 Although degradation of BIM is mainly regu-
lated by MAPK signaling, a number of other mechanisms, such 
as alternative splicing, transcriptional and posttranscriptional 
regulation, posttranslational modification, and epigenetic 
silencing also effects BIM expression.18 Recently, paired-
end DNA sequencing identified a deletion polymorphism in 
BIM.14 This polymorphism is located in intron 2 of the BIM 
gene that results in the expression of BIM isoforms lacking 
BH3 domain. This polymorphism is commonly found in the 
East Asian population yet absent in the Caucasian population. 
Intriguingly, lung cancer patients harboring this BIM germ 
line polymorphism have shorter progression free survival 
(PFS) to EGFR-TKIs14,19–22 thus contributing substantially to 
primary resistance. Tests to identify the BIM polymorphism 
in the clinic are being developed. Given the clinical signifi-
cance of the BIM polymorphism, we sought to investigate the 
relationship between this BIM polymorphism and the risk to 
develop lung cancer in general and lung cancer specifically 
with EGFR activating mutations.
PATIENTS AND METHODS
Subjects
All subjects were first-visit outpatients at the Aichi 
Cancer Center Hospital (ACCH) aged 18 to 79 who gave writ-
ten informed consent for enrollment in the Hospital-based 
Epidemiological Research Program at Aichi Cancer Center 
(HERPACC) during 2001–2005. Information on lifestyle fac-
tors was collected using a self-administered questionnaire, 
checked by a trained interviewer. The outpatients were also 
asked to provide blood samples. Approximately 95% of eli-
gible subjects completed the questionnaire and 60% provided 
blood samples. Details of this program have been described 
elsewhere.23,24 The lung cancer cases consisted of 765 patients 
who were newly and histologically diagnosed as having lung 
cancer. Controls (n = 942) were randomly selected from out-
patients who completed the questionnaire, provided blood 
samples, and were confirmed cancer free.25 The study protocol 
was approved by the ethics committee of Aichi Cancer Center 
and complied with the declaration of Helsinki.
Genotyping of the BIM Deletion 
Polymorphism and Other Polymorphisms
DNA of each subject was extracted from the buffy 
coat fraction using a DNA Blood mini kit (Qiagen, 
Tokyo, Japan) for the use of genotyping. Primers detect-
ing wild type BIM and BIM deletion polymorphism were 
developed previously.26 The primer sequences are F: 5′- 
CCACCAATGGAAAAGGTTCA-3′, R: 5′-CTGTCATTT 
CTCCCCACCAC-3′ for detecting wild-type BIM and F: 5′- 
CTGTCATTTCTCCCCACCAC-3′, R: 5′- GGCACAGCC 
TCTATGGAGAA-3′ for identifying the BIM deletion poly-
morphism. The primer pairs yield a 362 bp and 284 bp of PCR 
products, respectively. Screening was performed by primer sets 
identifying the BIM deletion polymorphism. DNA from PC-3 
cells, known to harbor the BIM deletion polymorphism, was used 
as a positive control. Positive samples were then determined to 
be homozygote or heterozygote by performing PCR with both 
primer sets. In addition to the BIM deletion polymorphism, 
genotyping data on 14 other polymorphisms (rs2289321, 
rs1439287, rs2015454, rs1837369, rs17041869, rs13396983, 
rs1877330, rs724710, rs3789068, rs17041887, rs616130, 
rs13405741, rs726430, rs9308742) that locate ±30,000-bp to 
the BIM polymorphism was adopted from previously genotyped 
data by an Illumina Human 610-Quad BeadChip (Illumina, San 
Diego, CA). Briefly, 576,736 SNP markers were examined at 
the Center for Genomic Medicine of Kyoto University Graduate 
School of Medicine. After removing SNPs that failed the qual-
ity control criteria (Hardy–Weinberg equilibrium p < 1 × 10−6 
[excluded SNPs: n = 277]; SNP call rate > 0.95 [n = 2921]; and 
minor allele frequency [MAF] < 0.01 [n = 82,414]), 491,738 
markers were selected as a source for this analysis (some SNPs 
were excluded based on two or more criteria).
Assessment of Smoking and Fruits and 
Green–Yellow Vegetable Intake
All exposures were assessed from the self-administered 
questionnaire, as completed at the first visit to ACCH before 
the diagnostic procedure was conducted. Subjects were ques-
tioned specifically about their lifestyle before the onset of the 
symptoms that prompted their visit to ACCH. Smoking sta-
tus was divided into three categories: never, former, and cur-
rent. Former smokers were defined as those who quit smoking 
at least 1 year before the time of the survey. The intake of 
fruits and green–yellow vegetables was determined using a 
food frequency questionnaire (FFQ), described in detail else-
where.25 Briefly, FFQ enables estimating quantity of intake by 
the information of frequency of the intake in eight categories: 
never or seldom, 1 to 3 times/month, 1 to 2 times/week, 3 to 4 
times/week, 5 to 6 times/week, once/day, twice/day, and three 
or more times/day. The intake was adjusted for total energy 
intake, and was classified into tertiles.
Clinicopathological Information
Clinicopathological information was obtained by 
linking clinical cohort data27 with HERPACC database. 
Pathological staging was based on UICC version 7. Mutation 
status of EGFR (exon 18 to 21) and KRAS (exon 1 and 2) 
were examined by sequencing of PCR products as previously 
described.28 EML4-ALK fusion was screened with RT-PCR 
and immunohistochemistry as described elsewhere.27
Statistical Analysis
Differences in categorized demographic variables 
between cases and controls were tested by a chi-squared test 
or Fisher’s exact test as appropriate. To verify that the allele 
distribution for each SNP was in the Hardy–Weinberg equi-
librium (HWE), we used a chi-squared test with one degree 
of freedom.
We applied odds ratios as measures of association and 
they and their 95% confidence intervals were estimated using 
unconditional logistic regression models adjusted for potential 
confounders. Potential confounders considered in this analysis 
were age, sex, smoking evaluated as pack-years (PY), and the 
energy-adjusted intake of fruit and green–yellow vegetables.
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We evaluated the association of the BIM deletion and 
selected polymorphisms within the major histological sub-
types of lung cancer (adenocarcinoma, squamous-cell carci-
noma, and small-cell carcinoma) and EGFR mutation status 
for those with information available. Survival probabilities 
were estimated by the Kaplan–Meier product limit method and 
comparisons between groups were tested by the log-rank test.
We used STATA version 13 (STATA Corporation, 
College Station, TX) for all analyses and adopted p value of 
less than 0.05 as statistically significant.
RESULTS
Patients Characteristics
Table 1 shows the difference in characteristics among 
cases and controls. Older subjects, males and heavier smokers 
made up a significantly higher number of the cases. Lower 
intake of fruit and vegetable trended higher in lung cancer 
cases but did not reach statistical significance. There is no dif-
ference between family history between cases and controls.
Association between BIM Deletion 
Polymorphism and Neighboring SNPs
The association between the BIM deletion polymor-
phism and neighboring SNPs and lung cancer risk are shown 
in Table 2. There is no violation of HWE among controls 
except rs13405741. As shown in Figure 1, there is a strong 
linkage disequilibrium in this region. The BIM deletion poly-
morphism as well as neighboring SNPs was shown to be a 
lack of statistically significant association with lung cancer 
risk (Table 2). These results suggest that a lung cancer suscep-
tibility locus is less likely to be included in this region.
No Difference of Frequency of the 
BIM Deletion Polymorphism between 
Controls and Lung Cancer Patients
We screened for the BIM deletion polymorphism in 765 
lung cancer cases and 942 healthy individuals. Carrier pos-
sessing one allele of the BIM polymorphism was observed 
in 13.0% of control and 12.8% of lung cancer cases. 
Homozygosity for the BIM polymorphism was observed in 
four of 942 controls and three of 765 lung cancer cases. The 
frequency of BIM polymorphism in lung cancer patients was 
not related to age, sex, smoking history or family history of 
lung cancer. Furthermore, these characteristics were not dif-
ferent between control and lung cancer cases (Table 3).
Lack of Association between the BIM 
Polymorphism and Histology and EGFR 
Mutation Status of Lung Cancer
To determine the association between lung cancer subtype 
and the BIM polymorphism, we examined the BIM polymor-
phism with histological lung cancer subtype (Table 4). Although 
the frequency of the BIM polymorphism was slightly lower in 
the small cell lung cancer subtype, no significant association 
of the BIM polymorphism and histological type was observed. 
Importantly, the BIM polymorpism was not associated with the 
risk of any histological subtype in lung cancer cases (Table 5). 
These results suggest a lack of association between lung can-
cer susceptibility and this BIM polymorphism. Furthermore, 
frequency of the BIM polymorphism was comparable among 
EGFR wild-type and EGFR mutant lung cancer patients, sug-
gesting lack of association between the BIM polymorphism and 
EGFR mutations in lung cancer (Table 4).
Impact of the BIM Polymorphism on the 
Survival of Early Stage Lung Cancer
To determine the natural history of lung cancers har-
boring the BIM polymorphism, we analyzed 139 stage I lung 
cancer cases who received complete surgical resection. The 
BIM polymorphism was identified in 15 patients, all of which 
are heterozygote. Clinical characteristics are shown in Table 
6. Survival of these stage I lung cancer patients was similar 
regardless of BIM polymorphism status (Fig. 2).
DISCUSSION
In this case-control study, we have shown that the fre-
quency of the BIM deletion polymorphism is approximately 
TABLE 1.  Characteristics of Subjects
Case  
(n = 765)
(%)
Controls  
(n = 942)
(%) p
Age
  <40 21 (2.7) 339 (36.0)
  40–49 60 (7.8) 155 (16.5)
  50–59 210 (27.5) 179 (19.0)
  60–69 295 (38.6) 176 (18.7)
  70- 179 (23.4) 93 (9.9) <0.001
Sex
  Male 564 (73.7) 492 (52.2)
  Female 201 (26.3) 450 (47.8) <0.001
Smoking
  Never 197 (25.8) 551 (58.5)
  Low 56 (7.3) 159 (16.9)
  Moderate 145 (19) 113 (12.0)
  Heavy 362 (47.3) 111 (11.8)
  Unknown 5 (0.7) 8 (0.8) <0.001
Fruit/Vegetable consumption
  Tertile 1 278 (36.3) 306 (32.5)
  Tertile 2 226 (29.5) 306 (32.5)
  Tertile 3 246 (32.2) 305 (32.4)
  Unknown 15 (2.0) 25 (2.7) 0.28
Family history of lung cancer
  No 731 (95.6) 896 (95.1)
  Yes 34 (4.4) 46 (4.9) 0.67
Histology
  Adenocarcinoma 450
  SCC 132
  SCLC 69
  Large 49
  Other/unknown 65
SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma.
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13% in Japanese population, comparable with the occur-
rence rate in the Chinese population.14,19,20 This BIM 
polymorphism was not associated with lung cancer sus-
ceptibility. Furthermore, the BIM polymorphism is not 
enriched in EGFR mutant lung cancers, nor does it appear 
to increase the risk of death of patients with stage I resected 
lung cancer.
Despite the lack of association between this BIM poly-
morphism and the acquisition of lung cancer, several stud-
ies have shown that SNPs in the apoptotic machinery are 
related to the risk of lung cancer. Multi-cohort genome wide 
association studies have identified genetic variants mapped 
to chromosomal regions 15q25 [nicotinic acetylcholine 
receptor (nAChR) subunits: CHRNA3, CHRNA5], 5p15 
FIGURE 1.  Linkage disequi-
librium plot of polymorphisms 
around BIM deletion polymor-
phism. LD (D′) plot of SNPs in 
BIM and adjacent regions. The 
color scheme is based on D′ and 
logarithm of the odds of linkage 
(LOD) score values: white, D′ < 
1 and LOD < 2; blue, D′ = 1 and 
LOD < 2; shades of pink/red, D′ 
< 1 and LOD ≥ 2; and bright red, 
D′ = 1 and LOD ≥ 2. The numbers 
in squares are D′ values (values 
of 1.0 are not shown). The map 
was drawn using Haploview. 
Haplotype blocks were identified 
by the software.
TABLE 2.  Association between SNPs around BIM Deletion Polymorphism and Lung Cancer Risk
Rs# Location Gene Miscellaneous
MAF in 
Cases
MAF in 
Controls
p Values for HWE 
Test in Controls pa
rs2289321 111870220 FIJ44006 In gene Intron 1 0.1538 0.1576 0.0094 0.543
rs1439287 111871897 FIJ44006 In gene 5′flk 0.3979 0.4091 0.4568 0.801
rs2015454 111872148 FIJ44006 In gene 5′flk 0.4483 0.4294 0.9264 0.324
rs1837369 111874276 LOC642268 Not in gene nearest 5′ 0.398 0.4119 0.4343 0.984
BIM deletion BCL2L11 In gene 0.068 0.069 0.8056 0.812
rs17041869 111896243 BCL2L11 In gene Intron 1 0.2346 0.2471 0.192 0.726
rs13396983 111900598 BCL2L11 In gene Intron 1 0.4516 0.4315 0.9559 0.338
rs1877330 111906762 BCL2L11 In gene Intron 1 0.2349 0.2442 0.1059 0.903
rs724710 111907691 BCL2L11 In gene Exon 2 0.0903 0.0961 0.1657 0.29
rs3789068 111909247 BCL2L11 In gene Intron 2 0.3986 0.4117 0.651 0.899
rs17041887 111910459 BCL2L11 In gene Intron 2 0 0 — NEb
rs616130 111912681 BCL2L11 In gene Intron 3 0.4541 0.4384 0.6983 0.238
rs13405741 111913056 BCL2L11 In gene Intron 3 0.0007 0.0048 0.8829 0.486
rs726430 111931421 BCL2L11 Not in gene — 0.2314 0.2463 0.2103 0.162
rs9308742 111943621 BCL2L11 Not in gene — 0.3889 0.4071 0.774 0.641
ap values for loci in logistic regression models including age, sex, smoking, fruit/vegetable consumption in tertile, and family history of lung cancers covariates with multiple 
imputations.
bNE indicates not estimated because of lack of subjects.
MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium.
63Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 BIM Deletion Polymorphism and Lung Cancer Risk
(TERT-CLPTM1L locus) and 6p21 (BAT3-MSH5) were 
associated with lung cancer risk,29,30 which was confirmed in 
the Japanese population as well.31 Some of these genes such 
as CLPTM1L and BAT3 may be involved in apoptosis.32 In 
addition, associations between SNPs in BCL2 family mem-
ber proteins and lung cancer risk have also been suggested.32 
However, loss of proapoptotic BCL2 family members itself 
does not appear sufficient to transform cells. Moreover, the 
level of BIM expression in EGFR mutant lung cancer did not 
affect the magnitude of apoptosis induction by DNA dam-
aging agents such as cisplatin,6 nor does it affect the PFS to 
chemotherapy.16,33 Understanding the precise role of apoptotic 
proteins in lung carcinogenesis might help to provide a strat-
egy for potential lung cancer therapeutics and chemopreven-
tion. Although the BIM polymorphism was not associated 
with lung cancer risk in this study, it does not exclude the 
possibility that the BIM polymorphism increases the risk of 
other cancers, especially hematological malignancies. The 
BIM polymorphism was originally found in chronic myeloid 
leukemia (CML) cells and associated with clinical resis-
tance to BCR-ABL inhibitors in patients with BCR-ABL 
positive CML.14 Furthermore, BIM knockout mice showed 
accumulation of lymphoid and myeloid cells, and resistance to 
apoptotic stimuli in lymphocytes.34
In this study, the incidence of BIM polymorphism was 
not related to EGFR mutation status in 332 patients. While 
there has been strong evidence from mouse experiments that 
BIM mitigates oncogene-induced tumors such as MYC35 and 
cyclin D1,36 other oncogenes directly downregulate BIM, like 
BCR-ABL, through the MEK/ERK pathway. Similarly, EGFR 
downregulates BIM directly through the MEK/ERK pathway, 
particularly the BIMEL isoform, therefore offering a differ-
ent way to downregulate functional BIM that may phenocopy 
the BIM polymorphism. Furthermore, numerous reports have 
highlighted differential ways cancers downregulate BIM at the 
RNA level, including through overexpression of microRNAs, 
genetic deletion, and epigenetic silencing. In EGFR mutant 
lung cancer cell lines, genetic LOH and micro-RNA-mediated 
downregulation was shown to lead to low BIM expression.6,37 
Additionally, other BIM polymorphisms may contribute to 
reduced BIM levels and efficacy of TKIs.38 Therefore, func-
tional BIM is downregulated via different mechanisms in 
EGFR mutant lung cancers, which would be overlooked by 
sole evaluation of the BIM deletion polymorphism.
TABLE 3.  Distribution of BIM Deletion Polymorphism Genotype According to Characteristics
Case (n = 765) Controls (n = 942)
No. Cases (%)
Wild-Type Heterozygote Homozygote Wild-Type Heterozygote Homozygote
664 (86.8) 98 (12.8) 3 (0.4) 816 (86.6) 122 (13.0) 4 (0.42)
Characteristics pa pa
Case-Control  
p Values
Age
  <40 19 1 1 301 37 1 0.095
  40–49 52 8 0 135 20 0 1
  50–59 178 32 0 154 25 0 0.78
  60–69 258 36 1 145 29 2 0.19
  70- 157 21 1 0.34 81 11 1 0.39 1
Sex
  Male 487 75 2 433 59 0 0.46
  Female 177 23 1 0.65 383 63 4 0.058 0.61
Smoking
  Never 171 25 1 475 73 3 0.96
  Low 44 12 0 142 16 1 0.055
  Moderate 128 17 0 99 14 0 1
  Heavy 318 42 2 94 17 0 0.52
  Unknown 3 2 0 0.25 6 2 0 0.73 1
Fruit/vegetable consumption
  Tertile 1 243 34 1 270 35 1 0.90
  Tertile 2 190 34 2 267 38 1 0.47
  Tertile 3 217 29 0 254 49 2 0.15
  Unknown 14 1 0 0.63 25 0 0 0.15 0.38
Family history of lung cancer
  No 632 96 3 780 112 4 0.92
  Yes 32 2 0 0.39 36 10 0 0.67 0.062
aFisher’s exact test.
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This study has several strengths and limitations. A nota-
ble strength is that this study was conducted in a single region 
in central Japan within the framework of the HERPACC study, 
with a substantial number of subjects and a high response rate 
to the completion of questionnaires and provision of blood 
samples. One limitation of the study is the problem of mul-
tiple testing although none of test for the association between 
BIM deletion polymorphism and susceptibility as well as sur-
vival showed statistical significance. The second limitation is 
the selection of controls: hospital-based outpatients who did 
not have a diagnosis of cancer. Nevertheless, both cases and 
controls were selected from the same framework, and most 
were residents of the same area (Aichi and its adjacent prefec-
tures), warranting the internal validity of this study.
Lastly, we did not find an association with survival of 
patients with Stage I lung cancer and the BIM polymorphism. 
FIGURE 2.  Overall survival according to BIM genotype. 
Overall survival for BIM deletion wt/wt and heterozygotes are 
drawn. No significant difference was shown by logrank test.
TABLE 6.  Characteristics of Stage IA/IB Patients According 
to BIM Deletion Genotypes
Wild-Type Heterozygote
Number of subjects 124 15
Median age 62 57
  (min, max) (26, 78) (47, 77)
Sex
  Male 66 8
  Female 58 7
pStage
  IA 41 4
  IB 83 11
EGFR mutation
  Wild-type 56 7
  Mutant 57 7
  Unknown 11 1
KRAS mutation
  Wild-type 68 9
  Mutant 6 2
  Unknown 50 4
ALK
  Wild-type 120 15
  Mutant 4 0
TABLE 4.  Prevalence of BIM Polymorphism Based on 
Histology and EGFR Mutation Status among Lung Cancer Cases
Number  
of 
Subjects Wild-Type Heterozygote Homozygote p
Histology
  Adenocarcinoma 450 380 69 1
  SCC 132 119 13 0
  SCLC 69 62 6 1
  Large 49 43 6 0
  Other/unknown 65 60 4 1 0.17
EGFR mutation
  Wild-type 212 182 30 0
  Mutant 120 104 16 0
  Unchecked 433 378 52 3 0.78
SCC, squamous cell carcinoma; SCLC, small cell lung carcinoma; Large, large cell 
carcinoma.
TABLE 5.  Impact of BIM Polymorphism on the Risk of Lung 
Cancer According to Histologic Subtype
Wild-Type Heterozygote Homozygote
Hetero or 
Homo
Controls (n) 816 122 4 126
Case overall (n) 664 98 3 101
  Adjusted ORa Reference 0.97 0.78 0.96
   95% CI — 0.69–1.36 0.13–4.58 0.69–1.34
   p — 0.86 0.79 0.83
Adenocarcinoma
  Number of  
  case
380 69 1 70
  Adjusted ORa Reference 1.15 0.55 1.13
   95% CI — 0.81–1.64 0.06–5.45 0.80–1.60
   p — 0.44 0.61 0.49
SCC
  Number of  
  case
119 13 0 13
  Adjusted ORa Reference 0.69 NEb 0.69
   95% CI — 0.33–1.43 — 0.33–1.42
   p — 0.32 — 0.31
SCLC
  Number of  
  case
62 6 1 7
  Adjusted ORa Reference 0.56 5.73 0.65
   95% CI — 0.22–1.45 0.28–116.8 0.26–1.59
   p — 0.23 0.26 0.35
aAdjusted for age, sex, smoking, fruit/vegetable consumption in tertile, and family 
history of lung cancer with multiple imputation.
bNE indicates not estimated because of lack of subjects.
OR, odds ratio; CI, confidence interval, SCC, squamous cell carcinoma; SCLC, 
small cell carcinoma.
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Low BIM expression does affect the survival time for patients 
with EGFR mutant advanced lung cancer, where surgical 
resection is not possible.16 Thus, the BIM polymorphism may 
similarly influence survival in advanced lung cancers.
Our study provides evidence that lung cancer risk and 
BIM polymorphisms are not significantly linked, indicating 
that genetic test of BIM deletion polymorphism is not neces-
sary for the screening of lung cancer among healthy individu-
als in the Japanese population. However, this BIM deletion 
polymorphism is a negative predictive factor of response to 
EGFR-TKI therapy.14,19,20 We have recently reported histone 
deacetylase inhibitor could restore functional BIM expres-
sion and circumvent EGFR-TKI resistance in EGFR mutant 
PC-3 and HCC2279 cells with the BIM polymorphism.26 
This combination is going to be assessed in a clinical trial 
(NCT02151721). Therefore, while this BIM polymorphism 
does not appear to be associated with a higher risk to develop 
lung cancer, its clinical utility to determine best treatment 
options appears quite significant.
In conclusion, in a large Japanese population, we report 
that the BIM polymorphism does not appear to increase the risk 
of EGFR mutant or EGFR wild type lung cancer, nor does it 
negatively impact the survival of stage I lung cancer patients.
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